Experimental Therapy Kills Prostate Tumors, Boosts Immunity
Researchers at Weill Cornell Medicine have developed silica-based nanoparticles that can directly kill prostate tumor cells while boosting the body's immune response. The study, conducted on mouse models, suggests a potential new clinical approach for treating aggressive cancer.
Why it matters
This breakthrough offers a promising dual-action therapy that could improve outcomes for patients with aggressive prostate cancer by making tumors more susceptible to immunotherapy.
Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing antitumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell Duffield College of Engineering.
Scientific reporting based on a published study without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in